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Multiple-synostosis syndrome is an autosomal dominant disorder characterized by progressive symphalangism,
carpal/tarsal fusions, deafness, and mild facial dysmorphism. Heterozygosity for functional null mutations in the
NOGGIN gene has been shown to be responsible for the disorder. However, in a cohort of six probands with
multiple-synostosis syndrome, only one was found to be heterozygous for a NOGGIN mutation (W205X). Linkage
studies involving the four-generation family of one of the mutation-negative patients excluded the NOGGIN locus,
providing genetic evidence of locus heterogeneity. In this family, polymorphic markers ﬂanking the GDF5 locus
were found to cosegregate with the disease, and sequence analysis demonstrated that affected individuals in the
family were heterozygous for a novel missense mutation that predicts an R438L substitution in the GDF5 protein.
Unlike mutations that lead to haploinsufﬁciency for GDF5 and produce brachydactyly C, the protein encoded by
the multiple-synostosis–syndrome allele was secreted as a mature GDF5 dimer. These data establish locus heter-
ogeneity in multiple-synostosis syndrome and demonstrate that the disorder can result from mutations in either
the NOGGIN or the GDF5 gene.
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Multiple-synostosis syndrome (SYNS1 [MIM 186500])
is an autosomal dominant condition characterized by
progressive joint fusions of the ﬁngers, wrists, ankles,
and cervical spine; characteristic facies; and progressive
conductive deafness. Two additional syndromes have
very similar phenotypes: proximal symphalangism
(SYM1 [MIM 185800]) and tarsal-carpal coalition syn-
drome (TCC [MIM 186570]). Heterozygosity forNOG-
GIN (GenBank accession number NM_005450) muta-
tions has been identiﬁed in all three disorders (Gong et
al. 1999; Dixon et al. 2001). In addition, heterozygosity
for mutations in NOGGIN has been identiﬁed in stapes
ankylosis syndrome without symphalangism (MIM
184460) (Brown et al. 2002). To date, 14 distinctNOG-
GIN mutations have been reported (Gong et al. 1999;
Dixon et al. 2001; Takahashi et al. 2001; Brown et al.
2002; Mangino et al. 2002). The majority (10 of 14)
are missense mutations, and the 4 nonsense mutations
are predicted to result in premature translation termi-
nation codons. Noggin was initially identiﬁed in Xen-
opus as a secreted signal released by the Spemann or-
ganizer and is involved in developmental processes,
including induction of neural tissue from the ectoderm
and dorsalization of the ventral mesoderm (Zimmerman
et al. 1996). It also participates in the regulation of chon-
drogenesis in somites and limb buds, in which it acts as
an antagonist to the bone morphogenetic proteins (Zim-
merman et al. 1996; Brunet et al. 1998; McMahon et
al. 1998).
GDF5 (growth differentiation factor 5, also known as
CDMP1 or BMP14), a member of the bone morpho-
genetic protein and TGF-b families, is a secreted growth
factor expressed during several steps in skeletal devel-
opment, including the formation of the cartilage anlagen
(chondrogenesis), chondrocyte differentiation, and joint
morphogenesis (Chang et al. 1994; Storm and Kingsley
1999). Several skeletal dysplasias are known to result
from mutations in GDF5 (GenBank accession number
NM_000557). Brachydactyly C (BDC [MIM 113100]),
a disorder characterized by shortened middle phalanges
of the second, third, and ﬁfth digits and by hyperphal-
angia, results from heterozygosity for functional null
www.ajhg.org The American Journal of Human Genetics Volume 78 April 2006 709
Figure 1 A, Pedigree of family R02-328 with SYNS1. B, Chromatograms showing the GDF5 wild-type (WT) sequence and the nucleotide
substitution, 1313GrT, predicted to lead to the amino acid substitution R438L.
GDF5 mutations (Polinkovsky et al. 1997). Recently, in
the disorder brachydactyly A2 (BDA2 [MIM 112600]),
heterozygosity for a GDF5 mutation (L441P) within the
active-signaling domain of the molecule was identiﬁed
(Kjaer et al. 2005). Homozygosity for functional null
mutations in GDF5 have been identiﬁed in autosomal
recessive Hunter-Thompson (MIM 201250), Grebe
(MIM 200700), and Du Pan (MIM 228900) chondro-
dysplasias, as well as in a rare form of BDC in the bra-
chypodism mouse (Storm et al. 1994; Thomas et al.
1996, 1997; Faiyaz-Ul-Haque et al. 2002; Schwabe et
al. 2004). Individuals with these disorders have severe
abnormalities in the bones and joints of the mesomelic
and acromelic limb segments. Interestingly, carriers of
the mutations of the recessive forms of GDF5 disorders
manifest mild abnormal metacarpohalangeal proﬁles,
which suggests gene-dose sensitivity in the developing
phalanges (Schwabe et al. 2004).
After obtaining institutional approval for human sub-
jects study, we studied a cohort of six genetically inde-
pendent individuals with SYNS1 diagnosed on the basis
of clinical and radiographic evaluations. Five cases oc-
curred sporadically, and one individual was a member
of a large four-generation Ashkenazi Jewish family (ﬁg.
1A). In this family, phenotypic ﬁndings included a broad
hemicyclindrical nose, progressive symphalangism, and
carpal, tarsal, and vertebral fusions. Within this family,
there was phenotypic variability in the extent of joint
fusions and in the presence or absence of equinovarus.
To test the hypothesis that heterozygosity forNOGGIN
mutations would lead to SYNS1 in this cohort, we de-
termined the sequence of the single exon encoding nog-
gin, using published methods (Gong et al. 1999). One
patient (R02-360) was heterozygous for a point muta-
tion (1425GrA) predicted to lead to a premature trans-
lation termination codon, W205X (human NOGGIN).
This mutation created an Afe1 restriction endonuclease
cleavage site, and the mutation was further conﬁrmed
by cleavage of a PCR-generated DNA fragment with the
enzyme (data not shown). No mutations were identiﬁed
in the remaining ﬁve probands. For two of the patients,
normal dosage of the NOGGIN gene was demonstrated
by Southern analysis (data not shown).
To conﬁrm the exclusion of NOGGIN as the disease
gene in the familial case of SYNS1, linkage analysis using
polymorphic markers from chromosome 17q21-22 was
performed. The data demonstrated exclusion of linkage
between the phenotype and the markersD17S787 (max-
imum LOD score of 0 [ ]) andD17S957 (maximumvp 0
LOD score of 1.0 [ ]), which ﬂank the NOGGINvp 0
gene, thus excluding NOGGIN as the disease gene. To
deﬁne the second locus for SYNS1, we considered other
genes known to be involved in joint morphogenesis, in-
cluding the gene encoding GDF5, which is a direct an-
tagonist of noggin. We tested linkage to the marker
D20S195, which is located 2.2 Mb centromeric to
710 The American Journal of Human Genetics Volume 78 April 2006 www.ajhg.org
Figure 2 Synthesis and secretion of normal and mutant GDF5 proteins. DF-1 cells transfected were control vector, human GDF5, chicken
(ch) GDF5, ch R438C-GDF5, and ch R438L-GDF5. A, Ponceau red-stained western blot demonstrating protein expression and uniform loading
in samples derived from the cell lysate and supernatant. B, Western blot analysis of lysate from ch GDF5 transfected cells showing pro-GDF5
in the human control lane and mature GDF5 in wild-type ch GDF5 and in ch R438L-GDF5 but not in ch R438C-GDF5 (top); western blot
analysis of supernatant from ch GDF5–transfected cells showing pro-GDF5 in the human control lane and mature GDF5 in wild-type ch GDF5
and in ch R438L-GDF5 but not in ch R438C-GDF5 (bottom).
GDF5. In the family, a single allele cosegregated with
disease without exception (maximum LOD score of 2.2
[ ]). Since these data supported the candidacy ofvp 0
theGDF5 gene, the sequences of the two exons ofGDF5
were determined as described elsewhere (Polinkovsky
et al. 1997) for the ﬁve NOGGIN mutation–negative
probands. Heterozygosity for a nucleotide substitution
(1313GrT) (humanGDF5) was found in the proband—
the index case from the large family—predicting an
R438L amino acid change in the protein (ﬁg. 1B). The
sequence change was found in all affected members of
the family but not in the unaffected individuals, and it
is predicted to substitute a hydrophilic arginine with a
hydrophobic leucine in a highly conserved residuewithin
the active-signaling domain of the mature protein. How-
ever, in four probands, neither a NOGGIN mutation
nor a GDF5 mutation was identiﬁed, which suggests
that other possible loci could lead to SYNS1.
To determine the consequences of the substitution on
dimerization and secretion of GDF5, we used an RCAS
viral construct (Lehmann et al. 2003) to transiently
transfect and express a chicken GDF5 cDNA carrying
the R438L sequence in DF-1 cells. The data were com-
pared with control constructs carrying either the wild-
type sequence or a cDNA with an R438C mutation,
which causes BDC (Everman et al. 2002). The BDC mu-
tation is known to lead to inefﬁcient dimerization and
secretion of the mature protein, which leads to func-
tional haploinsufﬁciency for GDF5 (Everman et al.
2002). Proteins secreted into the medium and within the
infected cells were each separated by PAGE under non-
reducing conditions, were transferred to membranes,
and were incubated with a monoclonal antibody to the
aminoterminal portion of GDF5 (kind gift from Bio-
pharm GmbH). The antibody recognizes the disulﬁde-
linked full dimer (pro-GDF5) and the mature, active-
domain dimer (GDF5) (Wang et al. 2004). The R438L
protein was assembled into mature GDF5 dimers and
was secreted in a similar way as wild-type GDF5 (ﬁg.
2B). In contrast, but consistent with prior studies (Ev-
erman et al. 2002), the R438C construct did not lead
to efﬁcient formation or secretion of either pro-GDF5
or mature GDF5 dimers. Thus, although the same amino
acid residue is altered in both BDC and SYNS1, the
different substitutions lead to distinct fates for the mu-
tant protein. It is likely that altered GDF5 activity due
to the R438L substitution, rather than due to haploin-
sufﬁciency, produces SYNS1, revealing an alternative
pathway to disease resulting from a GDF5 mutation
(Seeman et al. 2005)
To date, all reported mutations causing SYNS1 have
been heterozygous NOGGIN mutations (Marcelino et
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al. 2001). This report identiﬁes GDF5 as a second locus
for the SYNS1 phenotype. A role for GDF5 in joint
formation is further supported by the report of a large
family with features similar to SYNS1, described in ab-
stract form only (Akarsu et al. 1999). In the family, an
S475N substitution, also in the highly conserved active-
signaling domain of GDF5, was found to segregate with
the phenotype. The effects of the substitution on the
protein are unknown.
One of the questions raised by the identiﬁcation of a
second locus for SYNS1 is whether there are phenotypic
differences between the individuals in whom NOGGIN
versus GDF5 mutations have been identiﬁed. Detailed
review of the phenotypes of the individuals in the family
described here show characteristic clinical and radio-
graphic ﬁndings for the disorder, including a broad hem-
icyclindrical nose, progressive symphalangism, and car-
pal, tarsal, and vertebral fusions. Analysis of hand
radiographs of affected individuals showed no ﬁndings
characteristic of BDC, indicating that the substitution
does not result in an overlapping SYNS1/BDC pheno-
type. Detailed evaluation of this family did not reveal
any distinguishing clinical features between SYNS1 pa-
tients with NOGGIN mutations and patients with
GDF5 defects.
NOGGIN and GDF5 are both required for proper
joint morphogenesis. In the absence of noggin, BMP
growth factors are unregulated, resulting in chondrocyte
hyperplasia instead of apoptosis in the developing joint
and, thus, leading to lack of normal joint formation.
Noggin/ mice had a lethal skeletal phenotype with a
very abnormal skeleton, characterized by joint fusions
with a complete absence of limb joints, costovertebral
defects, and cartilage spurs, and with up-regulation of
GDF5 in the areas of the presumptive joints (Brunet et
al. 1998). Human NOGGIN mutations that lead to
SYNS1 are due to functional haploinsufﬁciency and a
presumed lack of appropriate antagonism of GDF5.
Since the GDF5 R438L protein is able to form mature
secreted dimers, we suggest the hypothesis that the mu-
tation leads to increased GDF5 activity and to SYNS1
(Seeman et al. 2005). This is mechanistically similar to
the consequences of haploinsufﬁciency for NOGGIN,
in that the resultant effect is the up-regulation of GDF5
in the mesenchyme surrounding the developing joint.
This study identiﬁes GDF5 as a locus for SYNS1. In
addition, mutations were not identiﬁed in either NOG-
GIN or GDF5 in the remaining four patients in the
cohort, suggesting the possibility of further locus
heterogeneity.
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